Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
CC transcript
Inv. presentation
Employment agrmnt

TITAN PHARMACEUTICALS INC (TTNP) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 SC 13D Sire Group Ltd. reports a 16.7% stake in Titan Pharmaceuticals, Inc.
10/04/2023 3 Sire Group Ltd. (10% Owner) has filed a Form 3 on TITAN PHARMACEUTICALS INC
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/31/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/31/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/31/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
07/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/31/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
07/20/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
07/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/29/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/28/2023 4/A Lazar David E. (CEO) has filed a Form 4 on TITAN PHARMACEUTICALS INC
Txns: Sold 3,388,902 shares @ $1.23, valued at $4.2M
Sold 359,066 shares @ $1.23, valued at $441.7k
06/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
05/19/2023 ARS Form ARS - Annual Report to Security Holders:
05/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/19/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Financial Statements and Exhibits  Interactive ...
01/26/2023 4 Lazar David E. (CEO) has filed a Form 4 on TITAN PHARMACEUTICALS INC
Txns: Bought 37,500 shares @ $0.9659, valued at $36.2k
Bought 20,000 shares @ $1.0033, valued at $20.1k
01/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
12/15/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
12/15/2022 8-K Quarterly results
12/12/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LICENSE AGREEMENT between TITAN PHARMACEUTICALS, INC. and OCULAR THERAPEUTIX, INC.",
"Titan Pharmaceuticals Announces Licensing Agreement with Ocular Therapeutix"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "THIS STAND-ALONE STOCK OPTION AGREEMENT dated as of the 15 th day of September, 2022 by and between Titan Pharmaceuticals, Inc., a Delaware corporation , and [●] ."
08/30/2022 3 Ben-Tzvi Avraham (Director) has filed a Form 3 on TITAN PHARMACEUTICALS INC
08/25/2022 3 McMurdo Matthew Charles (Director) has filed a Form 3 on TITAN PHARMACEUTICALS INC
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy